Scarica l'app Stockscreener
2.14
2.73%
-0.06
Precedente Chiudi:
$2.20
Aprire:
$2.21
Volume 24 ore:
135.02K
Relative Volume:
0.89
Capitalizzazione di mercato:
$109.04M
Reddito:
$96.63M
Utile/perdita netta:
$-63.32M
Rapporto P/E:
-1.0863
EPS:
-1.97
Flusso di cassa netto:
$-54.55M
1 W Prestazione:
-0.93%
1M Prestazione:
-23.57%
6M Prestazione:
+8.91%
1 anno Prestazione:
-52.97%
Intervallo 1D:
$2.11
$2.26
Intervallo di 1 settimana:
$2.055
$2.35
Portata 52W:
$1.88
$6.31
Akoya Biosciences Inc Stock (AKYA) Company Profile
Nome
Akoya Biosciences Inc
Settore
Industria
Telefono
855.896.8401
Indirizzo
100 CAMPUS DRIVE, MARLBOROUGH
Confronta AKYA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
2.14 | 109.04M | 96.63M | -63.32M | -54.55M | -1.97 |
|
ISRG
Intuitive Surgical Inc
|
538.55 | 192.83B | 7.87B | 2.24B | 586.00M | 4.25 |
|
BDX
Becton Dickinson Co
|
221.98 | 64.77B | 20.18B | 1.73B | 3.07B | 5.51 |
|
ALC
Alcon Inc
|
88.23 | 43.75B | 9.76B | 1.16B | 665.00M | 0.72 |
|
RMD
Resmed Inc
|
249.33 | 36.84B | 4.81B | 1.11B | 1.35B | 6.16 |
|
WST
West Pharmaceutical Services Inc
|
323.32 | 23.33B | 2.88B | 499.60M | 321.60M | 7.41 |
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-15 | Downgrade | Craig Hallum | Buy → Hold |
| 2024-08-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-08-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-21 | Iniziato | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-02-02 | Iniziato | UBS | Buy |
| 2022-11-03 | Iniziato | CapitalOne | Overweight |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-06-22 | Iniziato | BTIG Research | Buy |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-05-11 | Iniziato | Canaccord Genuity | Buy |
| 2021-05-11 | Iniziato | JP Morgan | Overweight |
| 2021-05-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-05-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Akoya Biosciences Inc Borsa (AKYA) Ultime notizie
Piper Sandler Reiterates “Overweight” Rating for Akoya Biosciences (NASDAQ:AKYA) - Defense World
Akoya Biosciences stock target cut, rating held on recent earnings report - Investing.com Canada
Akoya Biosciences' (AKYA) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA) - Simply Wall St
Time To Worry? Analysts Just Downgraded Their Akoya Biosciences, Inc. (NASDAQ:AKYA) Outlook - Yahoo Finance
Canaccord Genuity Group Issues Pessimistic Forecast for Akoya Biosciences (NASDAQ:AKYA) Stock Price - Defense World
Akoya Biosciences Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Akoya Biosciences shares target cut, maintains buy rating on Q3 results - Investing.com
Craig-Hallum Downgrades Akoya Biosciences (AKYA) - MSN
Akoya stock plunges 30% on outlook as Craig-Hallum cuts to hold - MSN
Akoya stock plunges 30% on outlook as Craig-Hallum cuts to hold (NASDAQ:AKYA) - Seeking Alpha
Akoya Biosciences (NASDAQ:AKYA) Price Target Cut to $3.50 by Analysts at Canaccord Genuity Group - MarketBeat
Akoya Biosciences (NASDAQ:AKYA) Stock Rating Lowered by Craig Hallum - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q3 2024 Earnings Call Transcript - Insider Monkey
Akoya Biosciences Shares Sink After FY24 Outlook Cut - MarketWatch
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Down 20.8% in October - MarketBeat
Akoya Biosciences, Inc. Revises Earnings Guidance for the Full Year 2024 - Marketscreener.com
Akoya: Q3 Earnings Snapshot - Darien Times
Akoya Biosciences Reports Q3 2024 Financial Results - TipRanks
Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Akoya Biosciences Reports Third Quarter 2024 Financial Results - GlobeNewswire
Akoya Biosciences earnings missed, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Akoya Biosciences Inc (AKYA) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt? - Simply Wall St
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Akoya Biosciences (AKYA) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Precision for Medicine to Offer Spatial Biology Solutions Incorporating the PhenoCycler®-Fusion 2.0 System and the new Phenocode™ Discovery IO60 Panel from Akoya Biosciences - PR Newswire
Akoya Biosciences Unveils a New Era in Spatial Content - GlobeNewswire
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel - Yahoo Finance
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Akoya Biosciences, Inc. (NASDAQ:AKYA) Sees Significant Decrease in Short Interest - MarketBeat
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024 - StockTitan
BTIG Downgrades Akoya Biosciences (AKYA) - MSN
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives $6.56 Consensus Price Target from Brokerages - MarketBeat
Akoya Biosciences (AKYA) Stock Price, News & Analysis - MarketBeat
Akoya Biosciences Inc (AKYA) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company - Simply Wall St
Akoya Biosciences joins UK cancer research initiative By Investing.com - Investing.com South Africa
Akoya Biosciences joins UK cancer research initiative - Investing.com India
Akoya’s Leading Spatial Proteomics Platforms Selected for - GlobeNewswire
Akoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy - The Manila Times
Akoya's Leading Spatial Proteomics Platforms Selected for Use by Uk-Based Manifest Consortium to Revolutionize Cancer Immunotherapy - Marketscreener.com
IPO Alert: Akoya Biosciences - RTTNews
Akoya Biosciences appoints new chairman By Investing.com - Investing.com South Africa
Akoya Biosciences Appoints Scott Mendel as Chairman of the Board of Directors - citybiz
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors - ForexTV.com
Akoya Biosciences appoints new chairman - Investing.com
Akoya Biosciences Inc Azioni (AKYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Akoya Biosciences Inc Azioni (AKYA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McKelligon Brian | President and CEO |
Jun 11 '24 |
Sale |
2.08 |
7,500 |
15,630 |
224,733 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
232,233 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Sale |
2.01 |
7,500 |
15,064 |
224,733 |
| McKelligon Brian | President and CEO |
Mar 20 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
239,368 |
| McKelligon Brian | President and CEO |
Mar 20 '24 |
Sale |
4.97 |
7,500 |
37,243 |
231,868 |
| McKelligon Brian | President and CEO |
Mar 13 '24 |
Sale |
4.94 |
7,500 |
37,035 |
224,368 |
| McKelligon Brian | President and CEO |
Dec 19 '23 |
Option Exercise |
0.30 |
7,500 |
2,272 |
160,063 |
| McKelligon Brian | President and CEO |
Dec 19 '23 |
Sale |
4.48 |
7,500 |
33,566 |
152,563 |
| McKelligon Brian | President and CEO |
Dec 12 '23 |
Option Exercise |
0.30 |
7,500 |
2,272 |
160,063 |
| McKelligon Brian | President and CEO |
Dec 12 '23 |
Sale |
4.25 |
7,500 |
31,871 |
152,563 |
0.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):